The Food and Drug Administration has issued its full stamp of approval for the Pfizer-BioNTech COVID-19 vaccine.
The move comes eight months after the vaccine was authorized for emergency use in the United States to battle rising cases of the coronavirus.
The FDA decision clears the way for the companies to market their vaccine, which is not permitted without full licensure.
It may also set off a race for booster shots, allowing doctors to prescribe extra shots “off label” to anyone they think should get one.
The decision may also lead to more companies, schools and other groups requiring vaccinations.
